Related Experiment Videos
SMN oligomerization defect correlates with spinal muscular atrophy severity
C L Lorson1, J Strasswimmer, J M Yao
1Department of Dermatology, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Abstract:
Spinal muscular atrophy (SMA) is a motor-neuron disorder resulting from anterior-horn-cell death. The autosomal recessive form has a carrier frequency of 1 in 50 and is the most common genetic cause of infant death. SMA is categorized as types I-III, ranging from severe to mild, based upon age of onset and clinical course. Two closely flanking copies of the survival motor neuron (SMN) gene are on chromosome 5q13 (ref. 1). The telomeric SMN (SMN1) copy is homozygously deleted or converted in >95% of SMA patients, while a small number of SMA disease alleles contain missense mutations within the carboxy terminus. We have identified a modular oligomerization domain within exon 6 of SMN1. All previously identified missense mutations map within or immediately adjacent to this domain. Comparison of wild-type to mutant SMN proteins of type I, II and III SMA patients showed a direct correlation between oligomerization and clinical type. Moreover, the most abundant centromeric SMN product, which encodes exons 1-6 but not 7, demonstrated reduced self-association. These findings identify decreased SMN self-association as a biochemical defect in SMA, and imply that disease severity is proportional to the intracellular concentration of oligomerization-competent SMN proteins.
Insights
Spinal muscular atrophy (SMA) is linked to decreased self-association of survival motor neuron (SMN) proteins. This protein defect correlates with SMA disease severity, impacting motor neuron health.
Area of Science:
- Genetics
- Molecular Biology
- Neuroscience
Background:
- Spinal muscular atrophy (SMA) is a severe genetic motor-neuron disorder caused by anterior-horn-cell death.
- It is the most common genetic cause of infant death, with a carrier frequency of 1 in 50.
- SMA is classified into types I-III based on clinical severity and age of onset.
Purpose of the Study:
- To investigate the role of the survival motor neuron (SMN) gene in SMA pathogenesis.
- To identify the biochemical defect underlying different clinical types of SMA.
- To explore the correlation between SMN protein oligomerization and disease severity.
Main Methods:
- Identification of a modular oligomerization domain within exon 6 of the SMN1 gene.
- Analysis of wild-type and mutant SMN proteins from SMA patients (types I-III).
- Comparison of SMN protein self-association in different SMA types and with a centromeric SMN product.
Main Results:
- A direct correlation was observed between SMN protein oligomerization and the clinical type of SMA.
- All previously identified missense mutations in SMA patients mapped to or near the identified oligomerization domain.
- The centromeric SMN product, lacking exon 7, showed reduced self-association.
Conclusions:
- Decreased SMN protein self-association is identified as a biochemical defect in spinal muscular atrophy.
- Disease severity in SMA is proportional to the concentration of oligomerization-competent SMN proteins.
- These findings offer insights into SMA pathogenesis and potential therapeutic targets.